Curaleaf
Leading vertically integrated medical and wellness cannabis operator.
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 184 % | 93 % | 10 % | 1 % | - | (3 %) | 6 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 26 % | 26 % | 14 % | 19 % | 21 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (10 %) | (8 %) | (28 %) | (21 %) | (16 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Curaleaf is a leading provider of cannabis products designed for both medical and recreational use. The company operates in the burgeoning cannabis market, serving a diverse clientele ranging from seasoned users to curious newcomers. Curaleaf's business model revolves around the cultivation, processing, and retailing of cannabis products, including tinctures, flowers, and edibles. The company leverages advanced encapsulation technology to enhance product absorption and efficacy, ensuring a superior user experience. Revenue is generated through direct sales at dispensaries and online platforms, as well as through medical consultations and guidance services. Curaleaf also engages in social responsibility initiatives, such as the B NOBLE program, which raises awareness and funds for individuals with non-violent, cannabis-related criminal charges.
Keywords: cannabis, medical, recreational, tinctures, edibles, absorption technology, dispensaries, consultations, B NOBLE, social responsibility.
Tech stack
Investments by Curaleaf
Edit
